{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-043781","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2026-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.991103+00:00","generated_at":"2026-05-15T06:01:27.095667+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Traws Pharma FY2025 net income $9.2M (vs loss $166.5M); $60M PIPE with $10M upfront funds into Q1 2027","bullets":["FY2025 net income $9.2M ($0.83 basic EPS) vs net loss $166.5M ($35.21 loss/share) in FY2024; revenue $2.8M (up from $0.2M).","Cash and equivalents $3.8M at Dec 31, 2025; PIPE up to $60M with $10M upfront to fund operations into Q1 2027.","TXM (influenza) Phase 1 bridging study ongoing; expects MHRA approval for human challenge trial in Q2 2026; FDA clinical hold unresolved.","Ratutrelvir (COVID) Phase 2a topline: faster symptom resolution in PAXLOVID-ineligible patients (HR 1.31, p=0.018); fewer adverse events vs comparator.","CEO Iain Dukes and CFO Charles Parker confirmed Oct 2025; John Leaman appointed independent director."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-043781","json":"https://secwatch.observer/filing/0001104659-26-043781.json","markdown":"https://secwatch.observer/filing/0001104659-26-043781.md","text":"https://secwatch.observer/filing/0001104659-26-043781.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926043781/0001104659-26-043781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926043781/tm2611843d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:01:27.095667+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}